scholarly journals Prognostic factors during androgen deprivation therapy in patients with hormone naive metastatic prostate cancer: is changes in hemoglobin level significant?

2018 ◽  
Vol 3 ◽  
pp. 92-92
Author(s):  
Daisaku Hirano ◽  
Toshiyuki Yoshida
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation ◽  
Hemoglobin Level

Usefulness of Prostate-Specific Antigen Nadir as Predictor of Androgen-Independent Progression of Metastatic Prostate Cancer

2005 ◽  
Vol 20 (4) ◽  
pp. 209-216 ◽  
Author(s):  
J. Morote ◽  
S. Esquena ◽  
J.M. Abascal ◽  
E. Trilla ◽  
L. Cecchini ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Gleason Score ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation ◽  
Bone Involvement ◽  
Free Survival ◽  
Psa Nadir

The objective of this study was to analyze the value of the nadir level of prostate-specific antigen (PSA) to predict androgen-independent progression (AIP) in metastatic prostate cancer patients after androgen deprivation therapy. In a group of 185 metastatic prostate cancer patients who received androgen deprivation therapy serum PSA was determined every three months until AIP occurred. Multiple regression analysis was performed to define independent clinical and PSA-related predictors of AIP. AIP was assumed to be present after two consecutive increases in serum PSA after the PSA nadir. Independent predictors of the duration of AIP-free survival (less than 12 months versus more than 12 months) were the extent of bone involvement (six or fewer hot spots versus more than six) with an odds ratio (O.R.) of 3.95, Gleason score (7 or less versus more than 7) with an O.R. of 3.47, and PSA nadir (2 μg/L or less versus more than 2 μg/L) with an O.R. of 14.63. AIP was independently predicted by the extent of bone involvement with an O.R. of 1.72, Gleason score with an O.R. of 1.74, PSA nadir with an O.R. of 3.22, and time to reach the PSA nadir (9 months or less versus more than 9 months) with an O.R. of 2.84. When patients were stratified according to these predictors, those with three good prognostic factors had a median AIP-free survival of 58 months while those with two, one or no good prognostic factors had a median AIP-free survival of 19 months, 12 months and 7 months, respectively. We conclude that the PSA nadir seems to be a good predictor of AIP in patients with metastatic prostate cancer after androgen deprivation therapy. Time to PSA nadir, extent of bone involvement and Gleason score are also independent predictors. The combination of these prognostic factors allows to stratify metastatic prostate cancer patients for the prediction of AIP.

scholarly journals Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer

2019 ◽  
Vol 39 (6) ◽  
pp. 3191-3195
Author(s):  
TAKESHI KOBAYASHI ◽  
RYO NAMITOME ◽  
YU HIRATA ◽  
MASAKI SHIOTA ◽  
KENJIRO IMADA ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
De Novo ◽  
Androgen Deprivation ◽  
Japanese Men

scholarly journals Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer

Cancer ◽  
2018 ◽  
Vol 125 (3) ◽  
pp. 453-462 ◽  
Author(s):  
Hala T. Borno ◽  
Daphne Y. Lichtensztajn ◽  
Scarlett L. Gomez ◽  
Nynikka R. Palmer ◽  
Charles J. Ryan
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation

A proposed link between spinal epidural lipomatosis, prostate cancer and androgen deprivation therapy

2017 ◽  
Vol 11 (4) ◽  
pp. 299-301 ◽  
Author(s):  
Isabel Tulloch ◽  
James T Laban ◽  
Andrew J Martin
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Spastic Paraparesis ◽  
Androgen Deprivation ◽  
Vertebral Metastases ◽  
Spinal Epidural Lipomatosis ◽  
Epidural Lipomatosis ◽  
Spinal Epidural

We present a patient with prostate cancer with vertebral metastases who developed spastic paraparesis secondary to spinal epidural lipomatosis (SEL) after receiving androgen deprivation therapy (ADT). We propose a link between ADT, metastatic prostate cancer and SEL.

Management of Metastatic Castrate-sensitive Prostate Cancer

2018 ◽  
Author(s):  
Derya Tilki ◽  
Marc A Dall’era ◽  
Christopher P Evans
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Survival Benefit ◽  
Metastatic Prostate Cancer ◽  
Oncologic Outcome ◽  
Standard Of Care ◽  
Abiraterone Acetate ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Treatment Paradigm

Oncologic outcome of patients with newly diagnosed metastatic prostate cancer (mPCa) is poor. The treatment paradigm for newly diagnosed mPCa has changed. The standard of care for men with metastatic hormone-naive prostate cancer has been systemic androgen deprivation therapy (ADT). Previous randomized studies demonstrated an overall survival benefit by the addition of early chemotherapy with six cycles of docetaxel. More recently, results from randomized trials also demonstrated a survival benefit by the addition of abiraterone acetate to the ADT in men with metastatic disease. The aim of this review is to summarize the results from most recent studies, including men with newly diagnosed metastatic hormone-naive prostate cancer, focusing on chemotherapy and ADT. This review contains 1 figure, 2 tables, and 47 references.  Key Words: abiraterone acetate, androgen deprivation therapy, androgen deprivation, castrate sensitive, chemotherapy, continuous androgen deprivation, docetaxel, hormone-naive, intermittent androgen deprivation, metastatic prostate cancer

Sign in / Sign up

Export Citation Format

Share Document